OM:VITRBiotechs
Vitrolife (OM:VITR) Is Down 24.1% After Impairment-Driven Loss And Maintained Dividend Proposal Has The Bull Case Changed?
Vitrolife AB reported fourth-quarter 2025 sales of SEK 891 million and a full-year net loss of SEK 5,012 million, while its Board proposed an unchanged dividend of SEK 1.10 per share for approval at the upcoming Annual General Meeting.
The sharp swing from prior-year profit to a very large loss, driven by impairment and restructuring costs, contrasts with continued organic sales growth and a maintained dividend proposal.
We’ll now examine how the large impairment-driven loss, alongside...